Do analysts rate ALDX or PRTC?

Aldeyra Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 189.47%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than PureTech Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 PureTech Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, ALDX or PRTC?

Aldeyra Therapeutics has higher earnings, but lower revenue than PureTech Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aldeyra Therapeutics N/A N/A -$33.85M -$0.46 N/A PureTech Health $4.66M 91.01 -$109.74M N/A N/A

Is ALDX or PRTC more profitable?

PureTech Health's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -57.34% -36.33% PureTech Health N/A N/A N/A

Which has better valuation and earnings, ANL or ALDX?

Aldeyra Therapeutics has lower revenue, but higher earnings than Adlai Nortye. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 87.92 -$35.53M N/A N/A Aldeyra Therapeutics N/A N/A -$33.85M -$0.46 N/A

Is ANL or ALDX more profitable?

Adlai Nortye's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A Aldeyra Therapeutics N/A -57.34% -36.33%

Is OCGN or ALDX more profitable?

Aldeyra Therapeutics has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Aldeyra Therapeutics' return on equity of -57.34% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen -1,192.18% -127,987.80% -135.48% Aldeyra Therapeutics N/A -57.34% -36.33%

Is ALDX or IPSC more profitable?

Century Therapeutics' return on equity of -49.89% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -57.34% -36.33% Century Therapeutics N/A -49.89% -37.42%

Aldeyra Therapeutics (ALDX) Competitors

$1.90 -0.12 (-5.94%)

Closing price 04:00 PM Eastern

Extended Trading

$2.01 +0.11 (+5.79%)

As of 06:36 PM Eastern

Compare

ALDX vs. PRTC, AUTL, ANL, OCGN, and IPSC

Should you buy Aldeyra Therapeutics stock or one of its competitors? MarketBeat compares Aldeyra Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aldeyra Therapeutics include PureTech Health (PRTC), Autolus Therapeutics (AUTL), Adlai Nortye (ANL), Ocugen (OCGN), and Century Therapeutics (IPSC). These companies are all part of the "pharmaceutical products" industry.

How does Aldeyra Therapeutics compare to PureTech Health?

Aldeyra Therapeutics (NASDAQ:ALDX) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PureTech Health shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 5.3% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

PureTech Health's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
PureTech Health	N/A	N/A	N/A

Aldeyra Therapeutics has higher earnings, but lower revenue than PureTech Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
PureTech Health	$4.66M	91.01	-$109.74M	N/A	N/A

Aldeyra Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, PureTech Health has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

In the previous week, PureTech Health had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 1 mentions for PureTech Health and 0 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.75 beat PureTech Health's score of 0.72 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aldeyra Therapeutics	Positive
PureTech Health	Positive

Aldeyra Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 189.47%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than PureTech Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PureTech Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Aldeyra Therapeutics beats PureTech Health on 8 of the 12 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Autolus Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Autolus Therapeutics (NASDAQ:AUTL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

59.7% of Aldeyra Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Autolus Therapeutics shares are held by institutional investors. 11.8% of Aldeyra Therapeutics shares are held by company insiders. Comparatively, 25.7% of Autolus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aldeyra Therapeutics has a net margin of 0.00% compared to Autolus Therapeutics' net margin of -311.98%. Aldeyra Therapeutics' return on equity of -57.34% beat Autolus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Autolus Therapeutics	-311.98%	-128.59%	-46.25%

Aldeyra Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 189.47%. Autolus Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 445.17%. Given Autolus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Autolus Therapeutics is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Autolus Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Aldeyra Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Autolus Therapeutics has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market.

Aldeyra Therapeutics has higher earnings, but lower revenue than Autolus Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Autolus Therapeutics	$75.39M	5.67	-$287.53M	-$1.09	N/A

In the previous week, Autolus Therapeutics had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 1 mentions for Autolus Therapeutics and 0 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.75 beat Autolus Therapeutics' score of 0.06 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aldeyra Therapeutics	Positive
Autolus Therapeutics	Neutral

Summary

Autolus Therapeutics beats Aldeyra Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Adlai Nortye had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 1 mentions for Adlai Nortye and 0 mentions for Aldeyra Therapeutics. Aldeyra Therapeutics' average media sentiment score of 0.75 beat Adlai Nortye's score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Adlai Nortye	Neutral
Aldeyra Therapeutics	Positive

Adlai Nortye has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 11.8% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aldeyra Therapeutics has lower revenue, but higher earnings than Adlai Nortye.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	87.92	-$35.53M	N/A	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

Adlai Nortye currently has a consensus price target of $24.25, suggesting a potential upside of 120.66%. Aldeyra Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 189.47%. Given Aldeyra Therapeutics' higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Adlai Nortye's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

Summary

Adlai Nortye and Aldeyra Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Ocugen?

Ocugen (NASDAQ:OCGN) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Aldeyra Therapeutics has lower revenue, but higher earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	106.70	-$67.85M	-$0.24	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

Aldeyra Therapeutics has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Aldeyra Therapeutics' return on equity of -57.34% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-127,987.80%	-135.48%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

In the previous week, Ocugen had 2 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 2 mentions for Ocugen and 0 mentions for Aldeyra Therapeutics. Ocugen's average media sentiment score of 1.45 beat Aldeyra Therapeutics' score of 0.75 indicating that Ocugen is being referred to more favorably in the media.

Company	Overall Sentiment
Ocugen	Positive
Aldeyra Therapeutics	Positive

Ocugen has a beta of 2.19, indicating that its stock price is 119% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

10.3% of Ocugen shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 4.0% of Ocugen shares are held by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ocugen currently has a consensus target price of $9.50, suggesting a potential upside of 583.45%. Aldeyra Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 189.47%. Given Ocugen's stronger consensus rating and higher possible upside, research analysts clearly believe Ocugen is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Ocugen beats Aldeyra Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Century Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Century Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aldeyra Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Century Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market.

Century Therapeutics' return on equity of -49.89% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
Century Therapeutics	N/A	-49.89%	-37.42%

In the previous week, Aldeyra Therapeutics' average media sentiment score of 0.75 beat Century Therapeutics' score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aldeyra Therapeutics	Positive
Century Therapeutics	Neutral

Aldeyra Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 189.47%. Century Therapeutics has a consensus target price of $4.75, suggesting a potential upside of 107.42%. Given Aldeyra Therapeutics' higher probable upside, research analysts plainly believe Aldeyra Therapeutics is more favorable than Century Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Century Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Century Therapeutics has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
Century Therapeutics	$109.16M	3.78	-$9.58M	-$1.14	N/A

Summary

Century Therapeutics beats Aldeyra Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Aldeyra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALDX vs. The Competition

Export

Metric	Aldeyra Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$121.85M	$2.99B	$6.74B	$12.32B
Dividend Yield	N/A	1.78%	2.68%	5.88%
P/E Ratio	-4.13	18.65	25.39	23.96
Price / Sales	N/A	341.96	530.17	107.90
Price / Cash	N/A	56.64	45.29	53.76
Price / Book	2.57	4.14	10.76	6.41
Net Income	-$33.85M	$64.45M	$3.56B	$337.14M
7 Day Performance	3.83%	1.34%	1.37%	-0.48%
1 Month Performance	22.58%	0.95%	0.81%	0.49%
1 Year Performance	-43.28%	24.33%	30.53%	28.16%

Aldeyra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALDX Aldeyra Therapeutics	2.9946 of 5 stars	$1.90 -5.9%	$5.50 +189.5%	-34.5%	$121.85M	N/A	N/A	10
PRTC PureTech Health	0.7752 of 5 stars	$17.42 flat	N/A	N/A	$424.04M	$4.66M	N/A	100
AUTL Autolus Therapeutics	3.6273 of 5 stars	$1.50 -3.8%	$8.75 +483.3%	-24.9%	$415.20M	$75.39M	N/A	330
ANL Adlai Nortye	1.5397 of 5 stars	$11.33 +9.8%	$24.25 +114.0%	+657.1%	$412.80M	$5M	N/A	127	Analyst Forecast
OCGN Ocugen	2.594 of 5 stars	$1.22 +0.8%	$9.50 +678.7%	+40.7%	$409.61M	$4.41M	N/A	80	Positive News Analyst Downgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALDX) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aldeyra Therapeutics (ALDX) Competitors

ALDX vs. PRTC, AUTL, ANL, OCGN, and IPSC

How does Aldeyra Therapeutics compare to PureTech Health?

Summary

How does Aldeyra Therapeutics compare to Autolus Therapeutics?

Summary

How does Aldeyra Therapeutics compare to Adlai Nortye?

Summary

How does Aldeyra Therapeutics compare to Ocugen?

Summary

How does Aldeyra Therapeutics compare to Century Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX vs. The Competition

Aldeyra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aldeyra Therapeutics (ALDX) Competitors

ALDX vs. PRTC, AUTL, ANL, OCGN, and IPSC

How does Aldeyra Therapeutics compare to PureTech Health?

Do insiders and institutionals have more ownership in ALDX or PRTC?

Is ALDX or PRTC more profitable?

Which has stronger earnings & valuation, ALDX or PRTC?

Which has more risk & volatility, ALDX or PRTC?

Does the media prefer ALDX or PRTC?

Do analysts rate ALDX or PRTC?

Summary

How does Aldeyra Therapeutics compare to Autolus Therapeutics?

Do insiders and institutionals believe in ALDX or AUTL?

Is ALDX or AUTL more profitable?

Do analysts recommend ALDX or AUTL?

Which has more risk & volatility, ALDX or AUTL?

Which has preferable valuation & earnings, ALDX or AUTL?

Does the media prefer ALDX or AUTL?

Summary

How does Aldeyra Therapeutics compare to Adlai Nortye?

Does the media favor ANL or ALDX?

Which has more volatility and risk, ANL or ALDX?

Do insiders & institutionals hold more shares of ANL or ALDX?

Which has better valuation and earnings, ANL or ALDX?

Do analysts rate ANL or ALDX?

Is ANL or ALDX more profitable?

Summary

How does Aldeyra Therapeutics compare to Ocugen?

Which has better earnings and valuation, OCGN or ALDX?

Is OCGN or ALDX more profitable?

Does the media favor OCGN or ALDX?

Which has more volatility and risk, OCGN or ALDX?

Do insiders and institutionals have more ownership in OCGN or ALDX?

Do analysts recommend OCGN or ALDX?

Summary

How does Aldeyra Therapeutics compare to Century Therapeutics?

Do insiders & institutionals hold more shares of ALDX or IPSC?

Which has more volatility & risk, ALDX or IPSC?

Is ALDX or IPSC more profitable?

Does the media prefer ALDX or IPSC?

Do analysts recommend ALDX or IPSC?

Which has better valuation & earnings, ALDX or IPSC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX vs. The Competition

Aldeyra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools